Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| Edwards Lifesciences (NYSE: EW) | Delayed: 95.19 +1.93 (2.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $93.26 | 52 Week High | $166.87 | |||
| Open | $93.67 | 52 Week Low | $72.20 | |||
| Day High | $96.09 | P/E | 27.67 | |||
| Day Low | $93.27 | EPS | $3.44 | |||
| Volume | 6,522,077 | |||||
